AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3891346 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine treatment
Number of subjects: 57
Study 30705235 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention including a 2-hour workshop on best-practice regarding BZD prescription, monthly feedback on prescribing practices, and access to a support web page
Number of subjects: 3
Study 30705235 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 3
Study 29842796 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour hospital stay (Group A)
Number of subjects: 432
Study 29842796 — intervention group
Group type: COMPARATOR
Intervention: Inpatient (Group B)
Number of subjects: 432
Study 26864586 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization exercises using the BALLance-Methode®
Number of subjects: 27
Study 26864586 — intervention group
Group type: COMPARATOR
Intervention: Core stability exercises
Number of subjects: 27
Study 24868146 — intervention group
Group type: COMPARATOR
Intervention: MMX mesalamine 4.8 g once daily
Number of subjects: 166
Study 22915730 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive outreach intervention (case management providing crisis intervention and flexible problem solving, including motivational support and assistance with appointments)
Number of subjects: 243
Study 22915730 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 243
Study 22915730 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive outreach intervention (self-reported data)
Number of subjects: 243
Study 22915730 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group, self-reported data)
Number of subjects: 243
Study 22915730 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive outreach intervention (imputed self-reported outcomes)
Number of subjects: 243
Study 22915730 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group, imputed self-reported outcomes)
Number of subjects: 243
Study 20385632 — intervention group
Group type: EXPERIMENTAL
Intervention: HIE-erythropoietin group (2500 IU/kg, subcutaneously, daily for 5 days)
Number of subjects: 30
Study 20385632 — intervention group
Group type: COMPARATOR
Intervention: HIE-control group (did not receive erythropoietin)
Number of subjects: 30
Study 20385632 — intervention group
Group type: COMPARATOR
Intervention: Normal healthy group
Number of subjects: 30
Study 17356051 — intervention group
Group type: COMPARATOR
Intervention: Basal plasma cortisol concentrations
Number of subjects: 177
Study 17356051 — intervention group
Group type: COMPARATOR
Intervention: Cosyntropin-stimulated plasma cortisol concentrations
Number of subjects: 177
Study 15241601 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling cues exposure in pathological gamblers
Number of subjects: 0
Study 15241601 — intervention group
Group type: COMPARATOR
Intervention: Gambling cues exposure in healthy controls
Number of subjects: 0
Study 11891019 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 week circuit training (CT) program
Number of subjects: 16
Study 10205211 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline injection
Number of subjects: 96
Study 10205211 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrocoagulation (gold probe)
Number of subjects: 96
Study 10205211 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (adrenaline injection and gold probe)
Number of subjects: 96
Study 10155359 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal pump
Number of subjects: 16
Study 10155359 — intervention group
Group type: COMPARATOR
Intervention: Roller pump
Number of subjects: 16
Study 2692728 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone at 14 mg/m2
Number of subjects: 0
Study 2692728 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone at 8 mg/m2
Number of subjects: 0
Study 2692728 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal bilirubin)
Number of subjects: 0
Study 2692728 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group with severe hepatic dysfunction
Number of subjects: 0
Study 2692728 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG level 0-2
Number of subjects: 0
Study 2692728 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG level 3
Number of subjects: 0
Study 2692728 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 0
Study 270863 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + hydrocortisone IT
Number of subjects: 24
Study 270863 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + hydrocortisone IT + TCT
Number of subjects: 24
Study 270863 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic treatment (previous series)
Number of subjects: 24
Study 30874471 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus dose epinephrine (BDE)
Number of subjects: 4374
Study 30874471 — intervention group
Group type: COMPARATOR
Intervention: Control (no BDE)
Number of subjects: 4374
Study 30371381 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive thresholding neurofeedback protocol
Number of subjects: 0
Study 30371381 — intervention group
Group type: COMPARATOR
Intervention: Current automatic reward thresholding algorithms
Number of subjects: 0
Study 26855267 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated chewing gum (100mg caffeine)
Number of subjects: 23
Study 26855267 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum (non-caffeinated)
Number of subjects: 23
Study 25845088 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise training (3 times/week for the first 3 months, then once/week for the following 9 months)
Number of subjects: 94
Study 25845088 — intervention group
Group type: COMPARATOR
Intervention: Control group (general lifestyle intervention suggestions)
Number of subjects: 94
Study 25845088 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise training (adherence level stratification)
Number of subjects: 94
Study 22404061 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (130/0.4)
Number of subjects: 7000
Study 22404061 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 7000
Study 20216298 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN) 500 mg/night titrated to 1500 mg/night for 12 weeks
Number of subjects: 19
Study 20216298 — intervention group
Group type: COMPARATOR
Intervention: Control (no ERN)
Number of subjects: 19
Study 20216298 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN)
Number of subjects: 19
Study 18065594 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Carnitine (2 g levocarnitine once daily)
Number of subjects: 66
Study 18065594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 15855557 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg repaglinide
Number of subjects: 16
Study 15855557 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg repaglinide
Number of subjects: 16
Study 15855557 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg and 4 mg repaglinide
Number of subjects: 16
Study 15855557 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg and 1 mg repaglinide
Number of subjects: 16
Study 15855557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12393571 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened patients for drug-dependent antibodies (DDABs)
Number of subjects: 1044
Study 12393571 — intervention group
Group type: COMPARATOR
Intervention: Nonscreened patients
Number of subjects: 1044
Study 10861613 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdermal injection of radiotracer on the tumor site plus a second injection of radiotracer (varied by group)
Number of subjects: 30
Study 10861613 — intervention group
Group type: EXPERIMENTAL
Intervention: Different route of injection (peritumoral or subdermal) on the tumor site
Number of subjects: 30
Study 10999057 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg, 6 hourly for 7 days)
Number of subjects: 75
Study 10999057 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic therapy (Control)
Number of subjects: 75
Study 1862191 — intervention group
Group type: EXPERIMENTAL
Intervention: Special video program based on perceptions of the effects of smoking during pregnancy
Number of subjects: 193
Study 1862191 — intervention group
Group type: EXPERIMENTAL
Intervention: American Lung Association's 'Freedom From Smoking For You and Your Baby' program
Number of subjects: 193
Study 1862191 — intervention group
Group type: COMPARATOR
Intervention: Usual physician's advice
Number of subjects: 193
Study 6314799 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutron boost radiotherapy after 50 Gy photon, whole-brain irradiation
Number of subjects: 158
Study 6314799 — intervention group
Group type: COMPARATOR
Intervention: Photon boost radiotherapy after 50 Gy photon, whole-brain irradiation
Number of subjects: 158
Study 6314799 — intervention group
Group type: COMPARATOR
Intervention: Photon boost group
Number of subjects: 158
Study 6314799 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutron boost group
Number of subjects: 158
Study 31553234 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib tablets (300 mg twice daily) until disease progression, unacceptable toxicity, or another discontinuation criterion.
Number of subjects: 0
Study 30249825 — intervention group
Group type: EXPERIMENTAL
Intervention: TPKE mode (n = 54)
Number of subjects: 108
Study 30249825 — intervention group
Group type: COMPARATOR
Intervention: LPKE mode (n = 54)
Number of subjects: 108
Study 26980371 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2495655 105 mg
Number of subjects: 400
Study 26980371 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2495655 315 mg
Number of subjects: 400
Study 26980371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 26980371 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2495655
Number of subjects: 400
Study 24458011 — intervention group
Group type: EXPERIMENTAL
Intervention: Treprostinil (delivered via cutaneous iontophoresis)
Number of subjects: 12
Study 24458011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22768889 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer application (CA) used by primary care physicians (PCPs)
Number of subjects: 697
Study 22768889 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CA used)
Number of subjects: 697
Study 20702056 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral+Evidential (PE)
Number of subjects: 771
Study 20702056 — intervention group
Group type: COMPARATOR
Intervention: Peripheral+Evidential+Socio-Cultural (PE+SC)
Number of subjects: 771
Study 17336417 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil, 8 mg/d (N=24)
Number of subjects: 47
Study 17336417 — intervention group
Group type: COMPARATOR
Intervention: No treatment (N=23)
Number of subjects: 47
Study 17336417 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (N=24)
Number of subjects: 47
Study 16341296 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 20
Study 16341296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Strength Training (CAST)
Number of subjects: 20
Study 16341296 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised Training (after 3 months of supervised training)
Number of subjects: 20
Study 12015902 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous administration of 12 million international units (MIU) of IL-2 followed by subcutaneous high-dose IL-2 (7.5 MIU, twice daily) for 5 days every 8 weeks
Number of subjects: 0
Study 12015902 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose subcutaneous IL-2 for 5 days every 8 weeks
Number of subjects: 0
Study 12015902 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose (3 MIU, twice daily) subcutaneous IL-2 for 5 days every 4 weeks
Number of subjects: 0
Study 12015902 — intervention group
Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 0
Study 9562580 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b (60 microg per square meter of body-surface area subcutaneously once weekly)
Number of subjects: 197
Study 9562580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 7947528 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg oestradiol implants
Number of subjects: 45
Study 7947528 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oestradiol implants
Number of subjects: 45
Study 7947528 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg oestradiol implants
Number of subjects: 45
Study 7947528 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 untreated women)
Number of subjects: 45
Study 3371393 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR (controlled-release), 100 mg once daily
Number of subjects: 195
Study 3371393 — intervention group
Group type: COMPARATOR
Intervention: Conventional metoprolol tablets, 100 mg once daily
Number of subjects: 195
Study 3371393 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR (controlled-release), 200 mg if needed
Number of subjects: 195
Study 3371393 — intervention group
Group type: COMPARATOR
Intervention: Conventional metoprolol tablets, 200 mg if needed
Number of subjects: 195
Study 3371393 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations of metoprolol
Number of subjects: 195
Study 30520221 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 388
Study 30520221 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 388
Study 29042333 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen (1 g every 6 hours up to 18 hours postoperatively)
Number of subjects: 140
Study 29042333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 140
Study 29042333 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 140
Study 27493113 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy for esophageal varices alone (group A)
Number of subjects: 47
Study 27493113 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment: esophagogastric devascularization with splenectomy followed by sclerotherapy (group B)
Number of subjects: 47
Study 25271603 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of immunologically active gluten daily
Number of subjects: 944
Study 25271603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 944
Study 22373943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 1217
Study 22373943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 1217
Study 22373943 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 1217
Study 22373943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1217
Study 19076988 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 28
Study 19076988 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 28
Study 18235409 — intervention group
Group type: EXPERIMENTAL
Intervention: First line chemotherapy based on a combination of pemetrexed and cisplatin
Number of subjects: 1000
Study 18235409 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic irradiation following drainage or thoracoscopy
Number of subjects: 1000
Study 18235409 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive extra‐pleural pneumonectomy
Number of subjects: 1000
Study 18235409 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiangiogenic agents such as bevacizumab (Avastatin)
Number of subjects: 1000
Study 15290003 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study 15290003 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 12518497 — intervention group
Group type: EXPERIMENTAL
Intervention: Surefil with Prime & Bond NT (Group A)
Number of subjects: 45
Study 12518497 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodigy Condensable with Optibond Solo (Group B)
Number of subjects: 45
Study 12518497 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel Plus with Prime & Bond NT (Group C)
Number of subjects: 45
Study 12518497 — intervention group
Group type: COMPARATOR
Intervention: Negative control (20 teeth without Class I preparations)
Number of subjects: 45
Study 9457906 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0
Study 9457906 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1)
Number of subjects: 0
Study 9457906 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide
Number of subjects: 0
Study 9457906 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal finger blood flow
Number of subjects: 0
Study 7557058 — intervention group
Group type: EXPERIMENTAL
Intervention: Teldane
Number of subjects: 12
Study 7557058 — intervention group
Group type: EXPERIMENTAL
Intervention: Feliberal
Number of subjects: 12
Study 3292002 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch isolation technique
Number of subjects: 236
Study 3292002 — intervention group
Group type: COMPARATOR
Intervention: Conventional resection technique
Number of subjects: 236
Study 19497245 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (300-450 mg/day) plus citalopram (60 mg/day)
Number of subjects: 76
Study 19497245 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus citalopram (60 mg/day)
Number of subjects: 76
Study 232026 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 9
Study 232026 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 9
Study 232026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31783742 — intervention group
Group type: EXPERIMENTAL
Intervention: Management for LTBI entirely within primary care (GPs and community pharmacists)
Number of subjects: 576
Study 31783742 — intervention group
Group type: COMPARATOR
Intervention: Referral to secondary care for LTBI management
Number of subjects: 576
Study 28240622 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 92
Study 28240622 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone + Propranolol
Number of subjects: 92
Study 25597463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinna Compensation (PC) feature
Number of subjects: 10
Study 25597463 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-Ear Coordinated Compression (IE)
Number of subjects: 10
Study 25597463 — intervention group
Group type: COMPARATOR
Intervention: Omnidirectional microphone (Omni)
Number of subjects: 10
Study 25597463 — intervention group
Group type: EXPERIMENTAL
Intervention: Omni microphone with PC feature
Number of subjects: 10
Study 25597463 — intervention group
Group type: EXPERIMENTAL
Intervention: Omni microphone with IE
Number of subjects: 10
Study 25597463 — intervention group
Group type: EXPERIMENTAL
Intervention: Omni microphone with both PC and IE features
Number of subjects: 10
Study 25597463 — intervention group
Group type: COMPARATOR
Intervention: Unaided localization performance
Number of subjects: 10
Study 22171722 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of Straumann implants (SLActive®)
Number of subjects: 266
Study 22171722 — intervention group
Group type: COMPARATOR
Intervention: Early loading of Straumann implants (SLActive®)
Number of subjects: 266
Study 21881030 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg)
Number of subjects: 146
Study 21881030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 18562409 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic drink
Number of subjects: 100
Study 18562409 — intervention group
Group type: COMPARATOR
Intervention: Non-alcoholic drink
Number of subjects: 100
Study 17267740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric gluconate 125 mg intravenously with eight consecutive hemodialysis sessions
Number of subjects: 134
Study 17267740 — intervention group
Group type: COMPARATOR
Intervention: No iron (control)
Number of subjects: 134
Study 15577140 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 15577140 — intervention group
Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 12143473 — intervention group
Group type: EXPERIMENTAL
Intervention: Optiflow dual lumen catheters at 350 ml/min
Number of subjects: 20
Study 12143473 — intervention group
Group type: EXPERIMENTAL
Intervention: Optiflow dual lumen catheters at 500 ml/min
Number of subjects: 20
Study 12143473 — intervention group
Group type: COMPARATOR
Intervention: PermCath dual lumen catheters at 300 ml/min
Number of subjects: 20
Study 9550167 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counseling plus enteral supplementation
Number of subjects: 118
Study 9550167 — intervention group
Group type: COMPARATOR
Intervention: Nutrition counseling alone (control group)
Number of subjects: 118
Study 8034880 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional coronary atherectomy
Number of subjects: 0
Study 8034880 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary angioplasty
Number of subjects: 0
Study 3294977 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 2 mg
Number of subjects: 150
Study 3294977 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 4 mg
Number of subjects: 150
Study 3294977 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 8 mg
Number of subjects: 150
Study 3294977 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 12 mg
Number of subjects: 150
Study 3294977 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 16 mg
Number of subjects: 150
Study 3294977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 31956928 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate supplementation
Number of subjects: 41
Study 31956928 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn starch)
Number of subjects: 41
Study 30799375 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary darbepoetin‐α 300 μg
Number of subjects: 80